可溶性肿瘤坏死因子受体Ⅰ在肝癌治疗前后的变化

Change of soluble tumor necrosis factor recepior Ⅰ level in the serum of patient with liver cancer after treatment

本文用双抗体夹心ELISA法检测了26例应用LAK细胞及肝动脉插管栓塞化疗的肝癌者治疗前后血清可溶性肿瘤坏死因子受体I的(sTNFRI)含量。结果显示正常成人血清sTNFRI含量为56.70±21.40u/ml,未治疗的肝癌患者血清sTNFRI含量为187.24±143.21u/ml,高于正常对照。而治疗后一周其sTNFRI水平又较治疗前明显升高。(P<0.01)从而提示;动态监测血清sTNFRI含量变化可能为肝癌患者的免疫状态,对治疗的反应以及病情变化提供参考。

Solubre tumor necrosis factor receptor I(sTNFR I) level in serum was measured with sandwich EKLISA in 26 Patients with liver cancer before and after treatment with lymphokine-activated killer (LAK) cells and/or by transarterial embolization (TAE). The results showed that pretreatment sTNFR I levels in the patients were higher than those in normal controls, sTNFR I levels were further increased after TAE or LAK+TAE treatment. And the differences were statisticaly significant(P<0.01). The fingding suggests that dynamic monitorying of sTNFR I level may be a necessary means for keeping informed on immne status, assessing response of the pationt to treatment and prognosis of the disease.